<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04114799</url>
  </required_header>
  <id_info>
    <org_study_id>UHradec Kralove</org_study_id>
    <nct_id>NCT04114799</nct_id>
  </id_info>
  <brief_title>Haemodynamical Optimization During Brain Surgery</brief_title>
  <official_title>A Comparison of Perioperative Fluid Management Using Invasive Haemodynamical Measurement of Fluid Responsiveness (Aisys GE) and Non-invasive Measurement of Haemodynamics (ClearSight System, Edwards) During Brain Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Hradec Kralove</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Hradec Kralove</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The decision to give fluids perioperatively could be based on methods used to identify
      preload responsiveness, either invasive or noninvasive estimates of stroke volume variation
      during mechanical ventilation. This study compares fluid management using invasive
      measurement SPV/PPV (Aisys GE) and noninvasive haemodynamic measurement (ClarSight, Edwards).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to optimise fluid management and to reduce perioperative risks during
      brain surgery. Adequate perioperative management guided by hemodynamic monitoring can help to
      reduce the risk of complications and thus potentially improve outcomes.

      This study compares fluid management algorithms based either on invasive detection of fluid
      responsiveness using pulse pressure variation (PPV) and systolic pressure variation (SPV)
      values (Aisys GE monitoring system) in group A, or on noninvasive measurement of
      haemodynamics (stroke volume variation (SVV), cardiac index (CI) and systemic vascular
      resistance (SVR) values) (ClearSight, Edwards) in group B.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fluid balance difference</measure>
    <time_frame>up to 5 hours after start of operation</time_frame>
    <description>the difference between fluid intake and output and losses during surgery will be calculated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean dose of norepinephrine</measure>
    <time_frame>up to 5 hours after start of operation</time_frame>
    <description>mean dose of norepinephrine will be calculated from total delivered dose devided by time of the surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of creatinin</measure>
    <time_frame>24 hours</time_frame>
    <description>plasma level of creatinin measured on the first postoperative day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative lung dysfunction</measure>
    <time_frame>1 day</time_frame>
    <description>postoperative lung dysfunction defined as SpO2 value less than 92% or oxygen therapy more than 6 hours postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of postoperative stay</measure>
    <time_frame>up to 2 month after surgery</time_frame>
    <description>number of days of stay in the hospital after the surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Brain Edema</condition>
  <arm_group>
    <arm_group_label>Group A invasive haemodynamical measurement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No continuous infusion of fluids will be used intraoperatively. A defined amount of fluid (20 ml of Plasmalyte, Baxter) will be used to flush the anesthetics and other drugs only. Fluid bolus will be applied in case of protocol defined hypotension according to the value of systolic pressure variation SPV (Aisys GE). The value of SPV (tidal volume 6 ml/kg) above 8% will be used to predict fluid responsiveness. In case of fluid responsiveness, bolus of 2ml/kg of Plasmalyte will be given within 10 minutes. Boluses will be repeated in hypotensive patients if fluid responsiveness persists. Norepinephrine will be used in hypotensive patients without predicted fluid responsiveness.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B non-invasive haemodynamical measurement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No continuous infusion of fluids will be used intraoperatively. A defined amount of fluid (20 ml of Plasmalyte, Baxter) will be used to flush the anesthetics and other drugs only. Fluid management and the use of norepinephrine will follow a protocol based on the values of cardiac index level, systemic vascular resistance and systolic volume variation (SVV) (ClearSight, Edwards).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hemodynamic management based on invasive fluid responsiveness parameters</intervention_name>
    <description>In case of hypotension (reduction of MAP for more than 15% of individual blood pressure) the SPV value more than 8% will be used as a trigger for the bolus of 2 ml/kg of Plasmalyte (Baxter)</description>
    <arm_group_label>Group A invasive haemodynamical measurement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hemodynamic management based on noninvasive cardiac output and SVV measurement</intervention_name>
    <description>In case of hypotension (reduction of MAP for more than 15% of individual blood pressure) the systemic vascular resistance (SVR) value will be used to trigger norepinephrine infusion. In patients with low SVR norepinephrine infusion will be started. In patients with high SVR value either fluid bolus (in patient with SVV value above 8%), or dobutamine infusion (in patients with SVV value below or equal 8%) will be used.</description>
    <arm_group_label>Group B non-invasive haemodynamical measurement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Glasgow Coma scale 15

          -  ASA Physical Status Classification System I-III

          -  planed surgery for brain tumor to 5 hours

          -  postoperative awakening

          -  sinus rhythm

        Exclusion Criteria:

          -  NYHA III, IV

          -  BMI over 40 in females and over 35 in men

          -  awake operation

          -  postoperative artificial ventilation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pavel Dostal, MD, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Hradec Kralove</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vlasta Dostálová, MD, Ph.D.</last_name>
    <phone>777883571</phone>
    <email>dostavla@seznam.cz</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pavel Dostal, MD, Ph.D.</last_name>
    <phone>+420495833218</phone>
    <email>pavel.dostal@fnhk.cz</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Dostal, MD, PhD</last_name>
      <phone>00420495833218</phone>
      <email>pavel.dostal@fnhk.cz</email>
    </contact>
    <contact_backup>
      <last_name>Pavel Dostal, MD, PhD</last_name>
      <phone>00420495832266</phone>
      <email>pavel.dostal@fnhk.cz</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 7, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2019</study_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Hradec Kralove</investigator_affiliation>
    <investigator_full_name>Dostalova Vlasta, MD, PhD</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>fluid responsiveness</keyword>
  <keyword>haemodynamical monitoring</keyword>
  <keyword>ClearSight</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

